drugset / Trial / NCT01488513
ABC294640 in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
22 enrolled
RedHill Biopharma Limited
Apogee Biotechnology Corporation · collabFDA Office of Orphan Products Development · collabMedical University of South Carolina · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.
Timeline
- Start
- 2011-08
- Primary completion
- 2014-08
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABC294640 | Small molecule | 250 mg | Oral |
| Subject | ABC294640 | Small molecule | 500 mg | Oral |
| Subject | ABC294640 | Small molecule | 750 mg | Oral |
| Subject | ABC294640 | Small molecule | 1000 mg | Oral |
| Subject | ABC294640 | Small molecule | 1500 mg | Oral |
| Subject | ABC294640 | Small molecule | 2000 mg | Oral |
| Subject | ABC294640 | Small molecule | 2500 mg | Oral |